 MONTREAL, Aug. 12, 2021 GLOBE NEWSWIRE -- Sunshine Biopharma Inc. OTC Pink: SBFM, a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it mapped the mutations found in Delta and the other variants of concern VOC identified to date and determined that the majority of the mutations are in the Spike protein and only a few fall within the genomic sequences that encode nsp3, a multi-domain protein that includes the PLpro enzyme. Serendipitously, no mutations mapped within the domain comprising the PLpro catalytic core. These finding indicate that our PLpro inhibitors currently under development at the University of Georgia would likely be effective against all of the VOC. 